HIV infection increases the risk of tuberculosis (TB). In the absence of antiretroviral therapy HIVinfected infants have a 24fold higher risk to develop TB disease compared to HIVuninfected infants in areas of high TB incidence. An increased incidence of congenital TB has also been noted.
Clinical features
Diagnosis of TB in children has always been challenging, but is now more complex because of overlap with other HIVrelated lung diseases. Both over and underdiagnosis are likely, depending on TB incidence and the health worker's experience.
Patient history
It is important to consider the following points when taking a history: ■ TB can present at any age, even in neonates. ■ Symptoms of pulmonary and extrapulmonary TB (EPTB) are more of ten acute in HIVinfected children. ■ WHO criteria for the diagnosis of TB (cough >2 weeks, failure to thrive, and/or weight loss) are more common in HIVinfected children than in HIVuninfected children with TB, but other HIVrelated conditions can cause similar symptoms. ■ Chronic fever is common in HIVassociated TB. ■ A history of contact with an adult TB source case is most important. This is often the first hint of diagnosis. A history of a known contact is identi fied in up to 66% of cases. ■ The drug susceptibility test results of the source case(s) are essential for the proper management of the childhood contacts. ■ Previous antituberculosis treatment in the child or the adult source case is associated with a higher rate of drug resistance.
A history of any of the following may indicate the need for invasive investigations to establish a definite diagnosis:
■ absence of an expected response to other treatments (e.g. antibiotics for two weeks); ■ previous abnormal chest radiograph findings; or ■ persistent lung disease.
Physical examination
■ Generally, children present with primary pulmonary TB that is more symptomatic than that found in HIVuninfected children. ■ EPTB affects similar sites in both HIVinfected and uninfected children. Peripheral lymph node and central nervous system (CNS) involvement are quite common. Unusual sites, such as the middle ear (causing chronic otorrhoea) need special attention. The increased association of EPTB with HIV infection is not as clear as it is in adults. Note that HIV disease itself results in generalized lymphadenopathy and hepatosplenomegaly. ■ There is an increased risk for TB in HIVinfected children without a BCG scar.
Special investigations Tuberculin skin test
A Mantoux tuberculin skin test (TST) should be per formed. The Mantoux TST consists of an intradermal injection of five tuberculin units (TU) of purified protein derivative (Japanese strain) or two TU of PPD RT23 (Danish strain). Induration is measured transversely in millimetres after 48 to 72 hours. A negative result does not exclude TB. For the HIVinfected child, induration >4 mm denotes a positive result. Repeating a negative TST after nutritional rehabi li tation in a severely malnourished child may yield a positive TST. Positive TST results are reported in 40% to 55% of HIV infected children with TB. Low CD4 counts and progressive HIV disease were associated with negative TST.
Interferon-gamma Release Assays (IGRAs)
IGRAs are specific Tcellbased assays developed to identify patients with TB infection. Two types of IGRAs are commercially available: the ELISAbased QuantiFERONTB Gold Intube assay (Cellestis Limited, Australia), and the ELISPOTbased TSpot.TB assay (Oxford Immunotec, UK). These assays have the same sensitivity for identifying TB infection as TST, but they have an increased specificity to TST in highburden areas of Most forms of extrapulmonary TB can be treated with the regimens mentioned above for between six to nine months. For patients with TB meningitis, six months of therapy with continuous rifampicin has been shown to be as effective as the traditional nine to 12 regimens. Lastly, ad junctive steroids may be useful in pericardial and meningeal tuberculosis (see Chapter 29: Cardiology and Chapter 35: Neurology).
Antituberculous therapy and antiretroviral therapy
Rifampicinbased antituberculous therapy can be given with nucleoside / nucleotide and nonnucleotide reverse transcriptase inhibitorbased ART, and antiretroviral therapy should not be interrupted. However rifampicin interacts with protease inhibitors and dose modification is required (see Chapter 49: Drugdrug interactions).
Antiretroviral therapy (ART) in patients newly diagnosed with TB should be started within two weeks provided the treatment for tubercu losis is being tolerated, social support is in place and adequate antiretro viral training has been given. Patients with a CD4 count >50 cells/µL have the option of starting ART after the first eight weeks of treatment for TB to reduce the risk of mild immune reconstitution disease (See Chapter 50: Immune reconstitution inflammatory syndrome).
Efavirenz is preferable to nevirapine when ART is initiated in tubercu losis patients. Tuberculosis patients who start nevirapine are at increased risk of virological failure as liver enzyme induction caused by rifampicin may cause subtherapeutic nevirapine levels when given during the first two weeks at a dose of 200 mg daily (if nevirapine is the best option con sider initiating treatment at 200 mg twice dialy). 
Side-effects of main antituberculous agents

